Non-inferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary HIV infection: a randomized, controlled, multi-site, open-label, non-inferiority trial

Braun, Dominique L; Turk, Teja; Tschumi, Fabian; Grube, Christina; Hampel, Benjamin; Depmeier, Carsten; Schreiber, Peter W; Brugger, Silvio D; Greiner, Michael; Steffens, Daniela; de Torrenté-Bayard, Cornelia; Courlet, Perrine; Neumann, Kathrin; Kuster, Herbert; Flepp, Markus; Bertisch, Barbara; Decosterd, Laurent; Böni, Jürg; Metzner, Karin J; Kouyos, Roger D; Günthard, Huldrych F

doi:10.1093/cid/ciy1131

Scientific article

English

Non-inferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary HIV infection: a randomized, controlled, multi-site, open-label, non-inferiority trial

Published inClinical Infectious Diseases, vol. 69, no. 9, p. 1489-1497

Publication date2019

Abstract

Patients who start combination antiretroviral therapy (cART) during primary HIV-1 infection show a smaller HIV-1 latent reservoir, less immune activation and a smaller viral diversity compared to patients who start cART during chronic infection. We conducted a pilot study to test whether these properties would allow sustained virological suppression after simplification of cART to dolutegravir monotherapy.

Keywords

Primary HIV infection
Dolutegravir
Monotherapy
Simplification
Randomized controlled trial

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de santé et médecine communautaires / Institut de santé globale

Research groups

Maladies infectieuses et modèles mathématiques (988)

Funding

Citation (ISO format)

BRAUN, Dominique L et al. Non-inferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary HIV infection: a randomized, controlled, multi-site, open-label, non-inferiority trial. In: Clinical Infectious Diseases, 2019, vol. 69, n° 9, p. 1489–1497. doi: 10.1093/cid/ciy1131